ReviewThe AAPS journal2026
Physiologically Based Pharmacokinetic (PBPK) Modeling of Oral Drug Absorption for Integrating Nonclinical Data into Human Pharmacokinetic Predictions.
Review in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and Evaluation of Physiologically Based Pharmacokinetic (PBPK) Models of Metoclopramide Across the Lifespan: Translation from Adults to Infants.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Intestinal Organoid-Based Mathematical Modeling Predicts Clinical Gastrointestinal Toxicity of Oral Oncology Drugs.CPT: pharmacometrics & systems pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of oral drug absorption is essential for anticipating variability in bioavailability and guiding clinical development. Physiological factors, such as gastric pH, gastric emptying, and intestinal transit time, influenced by food intake and acid-reducing agents (ARAs), play critical roles in the dissolution and absorption of drugs with pH-dependent solubility. Intestinal transporters and metabolizing enzymes also affect systemic exposure by regulating drug absorption, metabolism, and excretion in the intestine. Species differences in gastrointestinal physiology, including pH profiles, transporter expression, and motility patterns, present challenges when translating nonclinical data to humans. Physiologically based pharmacokinetic (PBPK) modeling offers a mechanistic framework to address these variations by integrating drug- and species-specific parameters. By calibrating in vitro and in vivo data, PBPK models can simulate human gastrointestinal conditions and more accurately predict oral absorption dynamics, enhancing translational relevance. These models facilitate early evaluation of food and ARA impacts, transporter-related absorption variabilities, and drug-drug interactions (DDIs), supporting the rational development of formulation and dose selection. Verifying model performance in nonclinical species, commonly in dogs, can further enhance confidence in human predictions. This review highlights drug- and species-specific factors and illustrates how PBPK modeling can address uncertainties regarding drug absorption in humans using nonclinical in vitro and in vivo data. Despite challenges such as parameter uncertainty and interspecies differences, PBPK modeling remains a valuable tool for estimating drug exposure and informing biopharmaceutical and clinical pharmacology strategies.
Indexed as
Identifiers
41857302What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.